Gillian Hall Sapia Gillian Hall Sapia

Series 5: Law: FDA Modernization Act 2.0 (2022)

Removing an outdated requirement is not the same as building a usable pathway. While the law allows human-relevant evidence, FDA has not consistently translated that permission into review standards. As a result, decades of registry data and academic research can still be acknowledged—and then dismissed—as “not sufficient,” simply because it does not fit trial frameworks built for common diseases.

Read More
Gillian Hall Sapia Gillian Hall Sapia

Eight Rare Laws, Zero Consistency: Series 1/9

Rare patients fought for the Orphan Drug Act because delay was already doing harm.


This post explains how the law was meant to work, where it has succeeded, and what happens when its protections quietly break down.

Read More
Gillian Hall Sapia Gillian Hall Sapia

Desperate and Uneducated: The Labels That Silence Rare Disease

Call us desperate if you want, but know this: desperate people get things done.

And if I am in that conference room when you use those words, I promise to stand up, grab the mic, and challenge that thought. Consider this your fair warning—I come with facts, stories, and just enough sass to make the whole room laugh while I set the record straight.

Read More